Beam Therapeutics Inc.’s base editing platform with BEAM-101 has trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug.
Beam Therapeutics has announced significant progress in its clinical trials and portfolio regarding precision genetic medicines, particularly in the area of sickle cell disease (SCD). Over 40 adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback